Back
CUSN
This asset is not currently listed on any markets available through Pearler. The information on this page may be inaccurate or out of date.
Copper Search Limited
๐ฆ๐บ ASX
๐ Overview
๐ Performance
๐ต Cost
๐ค Advanced
๐จโ๐ฉโ๐งโ๐ฆ Community
๐
N/A
Annual Growth
5 years average annual capital growth
๐ต
$ 500
Minimum Order
Due to regulatory requirements
๐
3
Pearlers Invested
Since January 2020
๐ Overview
Key information
๐ Fund Overview
Copper Search Limited - Ordinary Fully Paid Deferred
๐ Performance
Price History
N/A
1M
All Time
Graph
Table
Unsure how much or often to invest?
๐๏ธ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out โ๐ต Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out โโฑ๏ธ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out โ๐ต Costs
๐ผ
N/A
Management Fee
Included in unit price, not charged by Pearler
๐ธ
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
๐ธ Net fee calculator๐ค Advanced information
Technical Info
๐ฉโ๐ฉโ๐ฆ Community Insights
How our community is investing
๐ Pearlers invested in CUSN
0
๐ Total Capital Earnings
N/A
๐ Average investment frequency
N/A
๐ต Average investment amount
N/A
โฐ Last time a customer invested in CUSN
N/A
CUSN investor breakdown
๐ต Income of investors
More than 200k
150k - 200k
100k - 150k
50k - 100k
Less than 50k
๐ถ Age of investors
18 - 25
26 - 34
35 - 90
๐ Legal gender of investors
Female
Male
Pearlers who invest in CUSN also invest in...
VDHG.AX was created on 2017-11-20 by Vanguard. The fund's investment portfolio concentrates primarily on target outcome asset allocation. Vanguard Diversified High Growth Index ETF seeks to track the weighted average return of the various indices of the underlying funds in which it invests, in proportion to the Strategic Asset Allocation, before taking into account fees, expenses and tax.
๐ Performance (5Yr p.a)
8.18%
๐ Share price
$74.15 AUD
โณ๏ธ DIVERSIFIED
๐ GLOBAL
๐ HIGH PRICE GROWTH
Copper Search Ltd. is a mineral exploration and development company focused on the Gawler Craton Region of South Australia. The firm is engaged in targeting the copper-gold deposits within the Gawler Craton of South Australia. The Companyโs flagship Peake Project is in the NE Gawler Craton which is prospective for large-scale copper (IOCG) deposits. The company has over 20 shallow potential IOCG targets less than 500 meters (m) deep and a further six deeper targets at the project. The Project has been endowed with over 100 million tons of copper and 110 million ounces of gold. The project covers over 5,000 square kilometers. Its tenements are held through its 100%-owned subsidiary, Copper Search Australia Pty Ltd. Its tenements include Curdimurka, Anna Creek, Allandale, Stuarts Creek, Callana, Ruby Hill, Spring Hill, Mt Denison, and Blyth Creek. Its drilling aims to identify IOCG target deposits with similar scale potential to Prominent Hill and Carrapateena.
๐ Share price
$0.02 AUD
โ๏ธ MINING
Altitude Minerals Ltd is a AU-based company operating in Metals & Mining industry. Altitude Minerals Ltd, formerly Copper Search Limited, is an Australia-based mineral exploration company. The firm is engaged in targeting the copper-gold deposits within the Gawler Craton of South Australia. The Byrock Project covers 1,932 square kilometers (km2) located 80 kilometers (km) northeast of Bourke, New South Wales. The region is part of the Lachlan Fold Belt, which includes the Macquarie Arc and Cobar Basin - both of which contain operating mines. The Macquarie Arc is Australiaโs porphyry copper-gold province, hosting several mines, such as Newcrest Miningโs Cadia mine, Evolution Miningโs Northparkes and Cowal mines. The Peake Project is located in the Gawler Craton in South Australia. The Peake Project is made up of three areas and covers over 5,000 km2. Its Theseus Project is located 25km east of the operating Cowal Gold Mine in the southern Macquarie Arc of the Lachlan Fold Belt, NSW.
๐ Share price
$0.04 AUD
โ๏ธ MINING
VGS.AX was created on 2014-11-18 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard MSCI International Shares Index ETF seeks to track the return of the MSCI World ex-Australia Index (with net dividends reinvested) in Australian dollars before taking into account fees, expenses and tax.
๐ Performance (5Yr p.a)
18.14%
๐ Share price
$151.91 AUD
๐ GLOBAL
๐ค TECHNOLOGY
โณ๏ธ DIVERSIFIED
๐ HIGH PRICE GROWTH
A200.AX was created on 2018-05-07 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. The ETF currently has 8332.1m in AUM and 198 holdings. A200.AX aims to track the performance of an index (before fees and expenses) comprising 200 of the largest companies by market capitalisation listed on the ASX.
๐ Performance (5Yr p.a)
10.10%
๐ Share price
$149.77 AUD
๐ฆ๐บ AUSTRALIA
๐ธ FINANCIALS
โณ๏ธ DIVERSIFIED
๐ HIGH PRICE GROWTH
Want more shares? Try these...
Clinuvel Pharmaceuticals Ltd. operates as a biopharmaceutical company. The company is headquartered in Melbourne, Victoria. The company went IPO on 2001-02-13. The company is focused on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening, acute disorders, as well as healthcare solutions for specialized populations. Its lead therapy, SCENESSE (afamelanotide 16mg), is approved for commercial distribution in Europe, the United States of America, Israel, and Australia as the first systemic photoprotective drug for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). The company has operations in Europe, Singapore, and the United States of America. The company develops and manufactures NEURACTHEL (adrenocorticotropic hormone) in different formulations, to target neurological, endocrinological, and degenerative disorders. Its pharmaceutical product, PRENUMBRA, has been developed, and its use is to be expanded in the clinic from stroke to Parkinson's.
๐ Performance (5Yr p.a)
-9.86%
๐ Share price
$12.48 AUD
๐งฌ BIOTECHNOLOGY